

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “**US Securities Act**”) or securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States (as defined in Regulation S under the Securities Act (“**Regulation S**”)) or to, or for the account or benefit of, U.S. persons (as defined in Regulation S), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States. Accordingly, the securities mentioned herein will be offered and sold (i) in the United States only to qualified institutional buyers in reliance on the exemption from the registration requirements of the Securities Act provided by Rule 144A thereunder and (ii) outside the United States to non-U.S. persons in compliance with Regulation S.*



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3933)

**COMPLETION OF PLACING OF NEW SHARES
UNDER THE GENERAL MANDATE**

Sole Placing Agent and Sole Overall Coordinator



The Board is pleased to announce that all Conditions as set out in the Placing Agreement have been satisfied and Completion took place on 25 July 2025. An aggregate of 156,000,000 Placing Shares have been placed to not less than six Placees at the Placing Price per Placing Share pursuant to the terms and conditions of the Placing Agreement.

Reference is made to the announcement of The United Laboratories International Holdings Limited (the “**Company**”) dated 18 July 2025 (the “**Announcement**”) in relation to the placing of new Shares under the General Mandate (the “**Placing**”). Unless otherwise defined, capitalized terms used herein shall have the same meaning as defined in the Announcement.

COMPLETION OF PLACING

The Board is pleased to announce that all Conditions as set out in the Placing Agreement have been satisfied (including the granting of approval by the Listing Committee of the Stock Exchange for the listing of and permission to deal in the Placing Shares on the Stock Exchange) and Completion took place on 25 July 2025. An aggregate of 156,000,000 Placing Shares have been placed to not less than six Placees at the Placing Price of HK\$14.16 per Placing Share pursuant to the terms and conditions of the Placing Agreement.

The Placing Price of HK\$14.16 per Placing Share represents a discount of approximately 7.93% to the closing price of HK\$15.380 per Share as quoted on the Stock Exchange on the Last Trading Date and a discount of approximately 2.32% to the average closing price of approximately HK\$14.496 per Share as quoted on the Stock Exchange for the five (5) consecutive trading days immediately prior to the Last Trading Date.

To the best of the knowledge, information and belief of the Directors and having made all reasonable enquiries, the Placees and their respective ultimate beneficial owner(s), as applicable, are Independent Third Parties. None of the Placees has become a substantial Shareholder (as defined under the Listing Rules) of the Company immediately upon Completion.

USE OF PROCEEDS

The gross proceeds and the net proceeds (after deduction of the relevant expenses and fees) from the Placing amounted to HK\$2,209.0 million and HK\$2,168.2 million, respectively.

The Company intends to allocate the net proceeds from the Placing as follows:

- (a) approximately 60%, or HK\$1,300.9 million, will be used for capital expenditure related to the construction and expansion of the Company’s manufacturing facilities, including the Inner Mongolia plant and the Zhuhai plants, strengthen external collaboration, expand the Company’s international business, as well as other general corporate purposes; and

- (b) approximately 40%, or HK\$867.3 million, will be used for research and development of innovative product candidates, including the clinical trial of UBT251, and other pipelines under development.

The net proceeds from the Placing are expected to be fully utilized on or before 31 December 2028. Such expected time frame is based on the Board's best assessment, and is subject to adjustment depending on the Company's future development, market conditions and prevailing business circumstances.

SHAREHOLDING STRUCTURE OF THE COMPANY UPON COMPLETION OF THE PLACING

The Placing Shares represent:

- (a) approximately 8.59% of the total issued share capital of the Company immediately before Completion; and
- (b) approximately 7.91% of the total issued share capital of the Company as enlarged by the allotment and issuance of the Placing Shares upon Completion.

The table below sets out a summary of the shareholding structure of the Company immediately before and after Completion:

	Immediately before Completion		Immediately after Completion	
	Number of Shares	Approximate percentage of issued share capital	Number of Shares	Approximate percentage of issued share capital
Heren Far East Limited ⁽¹⁾	834,250,000	45.91%	834,250,000	42.28%
Mr. Tsoi Hoi Shan ⁽²⁾	16,498,575	0.91%	16,498,575	0.84%
Ms. Choy Siu Chit ⁽³⁾	207,475	0.01%	207,475	0.01%
Ms. Ning Kwai Chun ⁽⁴⁾	38,186,250	2.10%	38,186,250	1.93%
The Placees	-	-	156,000,000	7.91%
Other Shareholders	927,884,208	51.07%	927,884,208	47.03%
Total issued Shares	1,817,026,508	100.00%	1,973,026,508	100.00%

Notes:

- (1) Heren Far East Limited is a company that is indirectly wholly-owned by family trusts established for the benefits of the respective family members of Mr. Tsoi Hoi Shan, Ms. Choy Siu Chit and Ms. Ning Kwai Chun as the discretionary beneficiaries.
- (2) Mr. Tsoi Hoi Shan is our chairman and one of our executive Directors.
- (3) Ms. Choy Siu Chit is one of our executive Directors.
- (4) Ms. Ning Kwai Chun is the mother of Mr. Tsoi Hoi Shan and Ms. Choy Siu Chit.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 25 July 2025

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.